SE0201980D0 - Novel compounds - Google Patents
Novel compoundsInfo
- Publication number
- SE0201980D0 SE0201980D0 SE0201980A SE0201980A SE0201980D0 SE 0201980 D0 SE0201980 D0 SE 0201980D0 SE 0201980 A SE0201980 A SE 0201980A SE 0201980 A SE0201980 A SE 0201980A SE 0201980 D0 SE0201980 D0 SE 0201980D0
- Authority
- SE
- Sweden
- Prior art keywords
- novel compounds
- compounds
- diseases associated
- inhibitors
- cathepsin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0201980A SE0201980D0 (sv) | 2002-06-24 | 2002-06-24 | Novel compounds |
JP2004515329A JP2005533804A (ja) | 2002-06-24 | 2003-06-23 | システイン・プロテアーゼ活性に関係する疾患を処置するための新規プリン−もしくはピロール−[2,3−d]ピリミジン−2−カルボニトリル |
PCT/SE2003/001079 WO2004000843A1 (en) | 2002-06-24 | 2003-06-23 | NOVEL PURINE- OR PYRROLOL[2,3-d]PYRIMIDINE-2-CARBONITILES FOR TREATING DISEASES ASSOCIATED WITH CYSTEINE PROTEASE ACTIVITY |
US10/518,815 US7439240B2 (en) | 2002-06-24 | 2003-06-23 | Purine-or pyrrolol[2,3-d]pyrimidine-2-carbonitiles for treating diseases associated with cysteine protease activity |
AU2003243096A AU2003243096A1 (en) | 2002-06-24 | 2003-06-23 | NOVEL PURINE- OR PYRROLOL(2,3-d)PYRIMIDINE-2-CARBONITILES FOR TREATING DISEASES ASSOCIATED WITH CYSTEINE PROTEASE ACTIVITY |
DE60311272T DE60311272T2 (de) | 2002-06-24 | 2003-06-23 | Neue purin- oder pyrrolol(2,3-d)pyrimidin-2-carbonsäurenitrile zur behandlung von mit cysteinproteaseaktivität assoziierten krankheiten |
EP03761002A EP1532148B1 (en) | 2002-06-24 | 2003-06-23 | Novel purine- or pyrrolol(2,3-d)pyrimidine-2-carbonitiles for treating diseases associated with cysteine protease activity |
ES03761002T ES2279162T3 (es) | 2002-06-24 | 2003-06-23 | Nuevos purin- o pirrolo(2,3-d)pirimidin-2-carbonitrilos para tratar enfermedades asociadas con actividad de cisteina proteasa. |
US12/024,423 US20080119469A1 (en) | 2002-06-24 | 2008-02-01 | Novel Compounds |
US12/024,375 US20080125426A1 (en) | 2002-06-24 | 2008-02-01 | Novel Compounds |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0201980A SE0201980D0 (sv) | 2002-06-24 | 2002-06-24 | Novel compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
SE0201980D0 true SE0201980D0 (sv) | 2002-06-24 |
Family
ID=20288336
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SE0201980A SE0201980D0 (sv) | 2002-06-24 | 2002-06-24 | Novel compounds |
Country Status (8)
Country | Link |
---|---|
US (3) | US7439240B2 (zh) |
EP (1) | EP1532148B1 (zh) |
JP (1) | JP2005533804A (zh) |
AU (1) | AU2003243096A1 (zh) |
DE (1) | DE60311272T2 (zh) |
ES (1) | ES2279162T3 (zh) |
SE (1) | SE0201980D0 (zh) |
WO (1) | WO2004000843A1 (zh) |
Families Citing this family (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0117396D0 (en) | 2001-07-17 | 2001-09-05 | Glaxo Group Ltd | Chemical compounds |
AR036375A1 (es) | 2001-08-30 | 2004-09-01 | Novartis Ag | Compuestos pirrolo [2,3-d] pirimidina -2- carbonitrilo, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos compuestos para la preparacion de medicamentos |
SE0201980D0 (sv) * | 2002-06-24 | 2002-06-24 | Astrazeneca Ab | Novel compounds |
US8293751B2 (en) * | 2003-01-14 | 2012-10-23 | Arena Pharmaceuticals, Inc. | 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia |
EP1927594A1 (en) | 2003-01-14 | 2008-06-04 | Arena Pharmaceuticals, Inc. | 1,2,3-Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia |
GB0308208D0 (en) | 2003-04-09 | 2003-05-14 | Glaxo Group Ltd | Chemical compounds |
AU2004257267B2 (en) | 2003-07-14 | 2009-12-03 | Arena Pharmaceuticals,Inc | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto |
EP1724264A1 (en) * | 2004-03-10 | 2006-11-22 | Ono Pharmaceutical Co., Ltd. | Nitriles and medicinal compositions containing the same as the active ingredient |
TW200614993A (en) | 2004-06-11 | 2006-05-16 | Akzo Nobel Nv | 4-phenyl-pyrimidine-2-carbonitrile derivatives |
TW200745055A (en) * | 2005-09-23 | 2007-12-16 | Organon Nv | 4-Phenyl-6-substituted-pyrimidine-2-carbonitrile derivatives |
US7326715B2 (en) | 2005-09-23 | 2008-02-05 | N.V. Organon | 4-Phenyl-6-substituted-pyrimidine-2-carbonitrile derivatives |
TW200734338A (en) * | 2006-01-16 | 2007-09-16 | Organon Nv | 6-Phenyl-1H-imidazo [4,5-c] pyridine-4-carbonitrile derivatives |
US7687515B2 (en) | 2006-01-17 | 2010-03-30 | N.V. Organon | 6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives |
WO2007148064A1 (en) * | 2006-06-23 | 2007-12-27 | Astrazeneca Ab | Pteridine derivatives and their use as cathespin inhibitors |
US20090099157A1 (en) * | 2007-02-15 | 2009-04-16 | Ameriks Michael K | Tetrahydro-pyrazolo-pyridine thioether modulators of cathepsin s |
US20080269241A1 (en) * | 2007-02-15 | 2008-10-30 | Darin Allen | Bicyclic aminopropyl tetrahydro-pyrazolo-pyridine modulators of cathepsin s |
US20080207683A1 (en) * | 2007-02-15 | 2008-08-28 | Darin Allen | Biaryl-substituted tetrahydro-pyrazolo-pyridine modulators of cathepsin s |
US20080200454A1 (en) * | 2007-02-15 | 2008-08-21 | Ameriks Michael K | Carbon-linked tetrahydro-pyrazolo-pyridine modulators of cathepsin s |
US20090118274A1 (en) * | 2007-02-15 | 2009-05-07 | Darin Allen | Monocyclic aminopropyl tetrahydro-pyrazolo-pyridine modulators of cathepsin s |
EP2118106A1 (en) * | 2007-03-02 | 2009-11-18 | Glaxo Group Limited | Purines as cysteine protease inhibitors |
EP1972630A1 (en) * | 2007-03-02 | 2008-09-24 | Glaxo Group Limited | Purines as cysteine protease inhibitors |
TW200911803A (en) * | 2007-07-16 | 2009-03-16 | Organon Nv | 6-phenyl-1H-imidazo [4,5-c] pyridine-4-carbonitrile derivatives |
US7932251B2 (en) | 2007-07-16 | 2011-04-26 | N.V. Organon | 6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives |
WO2009107767A1 (ja) * | 2008-02-29 | 2009-09-03 | 大日本住友製薬株式会社 | H4受容体アンタゴニスト作用を有する新規2環性ピリミジン誘導体 |
US8193202B2 (en) | 2008-04-21 | 2012-06-05 | Lexicon Pharmaceuticals, Inc. | LIMK2 inhibitors, compositions comprising them, and methods of their use |
WO2010059418A1 (en) * | 2008-11-19 | 2010-05-27 | The Government Of The U.S.A. As Represented By The Secretary Of The Dept. Of Health & Human Services | Substituted triazine and purine compounds, methods of inhibiting cruzain and rhodesain and methods of treating chagas disease and african trypanosomiasis |
US8026236B2 (en) | 2009-01-16 | 2011-09-27 | N.V. Organon | 6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives |
TW201035094A (en) | 2009-01-16 | 2010-10-01 | Organon Nv | 6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives |
GB0917934D0 (en) | 2009-10-13 | 2009-11-25 | Syngenta Ltd | Herbicidal compounds |
EP2523954B1 (en) | 2010-01-15 | 2014-04-16 | Merck Sharp & Dohme B.V. | 1h-[1,2,3]triazolo[4,5-c]pyridine-4- carbonitrile derivatives as cathepsin s inhibitors |
KR101871011B1 (ko) | 2010-09-22 | 2018-06-25 | 아레나 파마슈티칼스, 인크. | Gpr119 수용체의 조절제 및 그와 관련된 장애의 치료 |
DK2626431T3 (en) | 2010-10-06 | 2015-12-21 | Fundació Inst De Recerca Biomèdica Irb Barcelona | A process for the diagnosis, prognosis and treatment of breast cancer metastasis |
EP2650682A1 (en) | 2012-04-09 | 2013-10-16 | Fundació Privada Institut de Recerca Biomèdica | Method for the prognosis and treatment of cancer metastasis |
US9328118B2 (en) * | 2012-04-17 | 2016-05-03 | Astellas Pharma Inc. | Nitrogen-containing bicyclic aromatic heterocyclic compound |
US10006091B2 (en) | 2012-06-06 | 2018-06-26 | Fundació Institut De Recerca Biomèdica (Irb Barcelona) | Method for the diagnosis, prognosis and treatment of lung cancer metastasis |
BR112015008255B1 (pt) | 2012-10-12 | 2023-02-28 | Inbiomotion S.L | Métodos in vitro para diagnóstico ou prognóstico de metástase óssea em um indivíduo com câncer de próstata e método para classificar um indivíduo que sofre de câncer de próstata em uma coorte |
US10119171B2 (en) | 2012-10-12 | 2018-11-06 | Inbiomotion S.L. | Method for the diagnosis, prognosis and treatment of prostate cancer metastasis |
CN104837839A (zh) | 2012-11-08 | 2015-08-12 | 辉瑞公司 | 作为多巴胺d1配体的杂芳族化合物 |
WO2014184679A2 (en) | 2013-03-15 | 2014-11-20 | Inbiomotion S.L. | Method for the prognosis and treatment of renal cell carcinoma metastasis |
JP6577873B2 (ja) | 2013-03-15 | 2019-09-18 | フンダシオ、インスティトゥト、デ、レセルカ、ビオメディカ(イエレベ、バルセロナ)Fundacio Institut De Recerca Biomedica (Irb Barcelona) | がんの転移の予後診断および処置のための方法 |
BR112016007864A2 (pt) | 2013-10-09 | 2017-12-05 | Fundacio Inst De Recerca Biomedica Irb Barcelona | método para a prognose e tratamento de metástase de câncer |
EP3137469B1 (en) | 2014-04-28 | 2019-10-09 | Pfizer Inc | Heterocyclic compounds and their use as dopamine d1 ligands |
JP6624594B2 (ja) | 2014-08-04 | 2019-12-25 | ヌエヴォリューション・アクティーゼルスカブNuevolution A/S | 炎症性、代謝性、腫瘍性および自己免疫疾患の処置に有用なピリミジンの任意選択により縮合されているヘテロシクリル置換誘導体 |
AU2015358868A1 (en) | 2014-12-11 | 2017-06-01 | Inbiomotion S.L. | Binding members for human C-Maf |
UA126268C2 (uk) | 2015-01-06 | 2022-09-14 | Арена Фармасьютікалз, Інк. | СПОСОБИ ЛІКУВАННЯ СТАНІВ, ПОВ'ЯЗАНИХ З РЕЦЕПТОРОМ S1P<sub>1 </sub> |
EA201890096A1 (ru) | 2015-06-22 | 2018-08-31 | Арена Фармасьютикалз, Инк. | КРИСТАЛЛИЧЕСКАЯ L-АРГИНИНОВАЯ СОЛЬ (R)-2-(7-(4-ЦИКЛОПЕНТИЛ-3-(ТРИФТОРМЕТИЛ)БЕНЗИЛОКСИ)-1,2,3,4-ТЕТРАГИДРОЦИКЛОПЕНТА[b]ИНДОЛ-3-ИЛ)УКСУСНОЙ КИСЛОТЫ (СОЕДИНЕНИЯ 1) ДЛЯ ПРИМЕНЕНИЯ ПРИ РАССТРОЙСТВАХ, СВЯЗАННЫХ С S1P-РЕЦЕПТОРОМ |
EP3901283A1 (en) | 2016-05-25 | 2021-10-27 | Inbiomotion S.L. | Therapeutic treatment of breast cancer based on c-maf status |
US11534424B2 (en) | 2017-02-16 | 2022-12-27 | Arena Pharmaceuticals, Inc. | Compounds and methods for treatment of primary biliary cholangitis |
WO2019102380A1 (en) | 2017-11-22 | 2019-05-31 | Inbiomotion S.L. | Therapeutic treatment of breast cancer based on c-maf |
KR102054910B1 (ko) * | 2017-12-19 | 2019-12-12 | 한림제약(주) | 피롤로[2,3-d]피리미딘 유도체 또는 이의 염 및 이를 포함하는 약학 조성물 |
US20220193048A1 (en) | 2019-04-05 | 2022-06-23 | Universite De Bretagne Occidentale | Protease-activated receptor-2 inhibitors for the treatment of sensory neuropathy induced by a marine neurotoxic poisoning |
JP2021098692A (ja) | 2019-12-20 | 2021-07-01 | ヌエヴォリューション・アクティーゼルスカブNuevolution A/S | 核内受容体に対して活性の化合物 |
MX2022012259A (es) | 2020-03-31 | 2022-12-08 | Nuevolution As | Compuestos activos frente a receptores nucleares. |
AU2021245397A1 (en) | 2020-03-31 | 2022-10-20 | Nuevolution A/S | Compounds active towards nuclear receptors |
WO2024105159A1 (en) * | 2022-11-16 | 2024-05-23 | University Of Zurich | Ligands of the m6a-rna readers |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000055125A2 (en) * | 1999-03-15 | 2000-09-21 | Axys Pharmaceuticals, Inc. | N-cyanomethyl amides as protease inhibitors |
JP2001011037A (ja) * | 1999-07-01 | 2001-01-16 | Kissei Pharmaceut Co Ltd | シクロアルカンカルボン酸アミド誘導体 |
EP1248790A1 (en) * | 1999-12-17 | 2002-10-16 | Ariad Pharmaceuticals, Inc. | Proton pump inhibitors |
UA72789C2 (en) * | 2000-02-04 | 2005-04-15 | Pfizer Prod Inc | Heterocyclic amide derivatives |
US6921753B2 (en) * | 2000-06-27 | 2005-07-26 | Pfizer Inc | Purine derivatives |
GB0015727D0 (en) * | 2000-06-27 | 2000-08-16 | Pfizer Ltd | Purine derivatives |
AU2001250570A1 (en) | 2000-10-19 | 2002-04-29 | Naeja Pharmaceutical Inc, | Dihydropyrimidine derivatives as cysteine protease inhibitors |
GB0121033D0 (en) | 2001-08-30 | 2001-10-24 | Novartis Ag | Organic compounds |
AR036375A1 (es) | 2001-08-30 | 2004-09-01 | Novartis Ag | Compuestos pirrolo [2,3-d] pirimidina -2- carbonitrilo, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos compuestos para la preparacion de medicamentos |
SE0201980D0 (sv) * | 2002-06-24 | 2002-06-24 | Astrazeneca Ab | Novel compounds |
SE0201976D0 (sv) * | 2002-06-24 | 2002-06-24 | Astrazeneca Ab | Novel compounds |
GB0220187D0 (en) * | 2002-08-30 | 2002-10-09 | Novartis Ag | Organic compounds |
PE20050068A1 (es) | 2003-02-06 | 2005-03-11 | Novartis Ag | 2-cianopirrolopirimidinas como inhibidores de la catepsina s |
GB0304640D0 (en) | 2003-02-28 | 2003-04-02 | Novartis Ag | Organic compounds |
EP1724264A1 (en) | 2004-03-10 | 2006-11-22 | Ono Pharmaceutical Co., Ltd. | Nitriles and medicinal compositions containing the same as the active ingredient |
WO2006040300A1 (en) | 2004-10-12 | 2006-04-20 | N.V. Organon | 4-cycloalkyl-pyrimidine-2-carbonitrile derivatives |
-
2002
- 2002-06-24 SE SE0201980A patent/SE0201980D0/xx unknown
-
2003
- 2003-06-23 DE DE60311272T patent/DE60311272T2/de not_active Expired - Fee Related
- 2003-06-23 JP JP2004515329A patent/JP2005533804A/ja active Pending
- 2003-06-23 EP EP03761002A patent/EP1532148B1/en not_active Expired - Lifetime
- 2003-06-23 AU AU2003243096A patent/AU2003243096A1/en not_active Abandoned
- 2003-06-23 WO PCT/SE2003/001079 patent/WO2004000843A1/en active IP Right Grant
- 2003-06-23 US US10/518,815 patent/US7439240B2/en not_active Expired - Fee Related
- 2003-06-23 ES ES03761002T patent/ES2279162T3/es not_active Expired - Lifetime
-
2008
- 2008-02-01 US US12/024,423 patent/US20080119469A1/en not_active Abandoned
- 2008-02-01 US US12/024,375 patent/US20080125426A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP1532148B1 (en) | 2007-01-17 |
US7439240B2 (en) | 2008-10-21 |
AU2003243096A1 (en) | 2004-01-06 |
US20050203107A1 (en) | 2005-09-15 |
DE60311272D1 (de) | 2007-03-08 |
EP1532148A1 (en) | 2005-05-25 |
US20080119469A1 (en) | 2008-05-22 |
JP2005533804A (ja) | 2005-11-10 |
ES2279162T3 (es) | 2007-08-16 |
WO2004000843A1 (en) | 2003-12-31 |
US20080125426A1 (en) | 2008-05-29 |
DE60311272T2 (de) | 2007-11-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SE0201980D0 (sv) | Novel compounds | |
CY1107342T1 (el) | Χρηση παραγωγων νιτριλιου ως φαρμακο | |
SE0201976D0 (sv) | Novel compounds | |
ATE387197T1 (de) | Cyanoalkylamino-derivate als protease-hemmer | |
NO20061627L (no) | Haloalkyl inneholdende forbindelser som cysteinproteaseinhibitorer | |
YU17402A (sh) | Nova spiroheterociklična jedinjenja upotrebljiva kao reverzibilni inhibitori cisteinskih proteaza | |
IS7925A (is) | Hýdroxýetýlamínafleiður til að meðhöndla Alzheimers-sjúkdóm | |
ATE483692T1 (de) | Als beta-sekretase (bace)-hemmer nützliche 2- amino-chinazolinderivate | |
DE602005023887D1 (de) | Als b-sekretase (bace)-hemmer nützliche 2-amino-chinazolinderivate | |
TR200002940T2 (tr) | Parazitlerin sebep olduğu hastalıkların papain süperfamilyasından sistein proteazların inhibisyonu yoluyla tedavisi | |
TW200700057A (en) | Alpha ketoamide compounds as cysteine protease inhibitors | |
WO2003029200A3 (en) | Compounds useful as reversible inhibitors of cysteine proteases | |
WO2005074904A3 (en) | Silinane compounds as cysteine protease inhibitors | |
SE0203712D0 (sv) | Novel compounds | |
DK1539724T3 (da) | Aminobenzothiazolforbindelser med NOS-inhiberende aktivitet | |
TW200509919A (en) | Cathepsin S inhibitors | |
MX2007011739A (es) | Compuestos que contienen sulfonilo como inhibidores de cisteina proteasa. | |
WO2005063742A3 (en) | Amidino compounds as cysteine protease inhibitors | |
MX2009003563A (es) | Compuestos que contienen di-fluoro como inhibidores de proteasa de cisteina. | |
WO2002023784A3 (en) | Cysteine protease inhibitors | |
CR6462A (es) | Compuestos y composiciones como inhibidores de proteaso |